Rising from the Ashes
MDCO's Cangrelor Succeeds in Phase III PHOENIX Study
Despite a clinical setback in 2009, when two massive Phase III trials of cangrelor were halted for lack of apparent efficacy, the antiplatelet candidate is back on track, as The Medicines Co. reported positive results from a new Phase III study.